Clinical trial

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

NCT05024214

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2021-11-15

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2021-11-15Date precision: day

Registry last updated2026-03-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Solid Tumorsunresolved

Non-small Cell Lung Cancerunresolved

Renal Cell Carcinomaunresolved

Hepatocellular Carcinomaunresolved

Interventions

Lenvatinib + EnvafolimabDRUG

SunitinibDRUG · verified · RxNorm: sunitinib

Sponsors & collaborators

3D Medicines (Sichuan) Co., Ltd.lead sponsor

Mapped research locations

BeijingBeijing Municipality, China2 ChangchunJilin, China2 ShenyangLiaoning, China2 GuangzhouGuangdong, China1 ShanghaiChina1 HangzhouZhejiang, China1 JinanShandong, China1 ZhengzhouHenan, China1 TianjinTianjin Municipality, China1 FuzhouFujian, China1 NanchangJiangxi, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05024214 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.